Molecular Oncology (Jun 2024)

Novel RAF‐directed approaches to overcome current clinical limits and block the RAS/RAF node

  • Rossella Scardaci,
  • Ewa Berlinska,
  • Pietro Scaparone,
  • Sandra Vietti Michelina,
  • Edoardo Garbo,
  • Silvia Novello,
  • David Santamaria,
  • Chiara Ambrogio

DOI
https://doi.org/10.1002/1878-0261.13605
Journal volume & issue
Vol. 18, no. 6
pp. 1355 – 1377

Abstract

Read online

Mutations in the RAS–RAF–MEK–ERK pathway are frequent alterations in cancer and RASopathies, and while RAS oncogene activation alone affects 19% of all patients and accounts for approximately 3.4 million new cases every year, less frequent alterations in the cascade's downstream effectors are also involved in cancer etiology. RAS proteins initiate the signaling cascade by promoting the dimerization of RAF kinases, which can act as oncoproteins as well: BRAFV600E is the most common oncogenic driver, mutated in the 8% of all malignancies. Research in this field led to the development of drugs that target the BRAFV600‐like mutations (Class I), which are now utilized in clinics, but cause paradoxical activation of the pathway and resistance development. Furthermore, they are ineffective against non‐BRAFV600E malignancies that dimerize and could be either RTK/RAS independent or dependent (Class II and III, respectively), which are still lacking an effective treatment. This review discusses the recent advances in anti‐RAF therapies, including paradox breakers, dimer‐inhibitors, immunotherapies, and other novel approaches, critically evaluating their efficacy in overcoming the therapeutic limitations, and their putative role in blocking the RAS pathway.

Keywords